MXCT
NASDAQ
$1.17
MaxCyte Inc (MXCT)
MaxCyte Inc. (MXCT) is a leader in cell-engineering, renowned for its innovative Flow Electroporation® technology that enables efficient and scalable delivery of nucleic acids and proteins into a variety of cell types. The company serves a prestigious clientele, including top biopharmaceutical firms and research institutions, positioning it favorably within the rapidly expanding cell and gene therapy market. MaxCyte's advanced platforms play a crucial role in the development of novel cell-based therapies and vaccines, responding to the growing global demand for transformative healthcare solutions. With a steadfast commitment to enhancing patient outcomes, MaxCyte is poised to capitalize on significant market opportunities in the life sciences sector.
Sector:
Healthcare
Industry:
Medical Devices
Buy
Target: $4.11 (+251.03%)
Market Cap
$152M
P/B Ratio
0.91
Free Cash Flow Yield
-19.30%
Beta (5Y)
1.30
Price Chart
Valuation
Market Cap$152M
P/S4.71
P/B0.91
Profitability
Total Revenue (TTM)$20M
Gross Profit (TTM)$26M
EBITDA-$41M
Profit Margin-121.2%
Operating Margin-64.1%
EPS-$0.37
Financial Health
Free Cash Flow Yield-19.30%
Growth & Risk
EPS 5Y CAGR+12.02%
Revenue 5Y CAGR+0.02%
Beta (5Y)1.30
Sharpe Ratio-0.49